Belimumab, a monoclonal antibody targeting B-lymphocyte stimulator (BLyS), is FDA-approved for systemic lupus erythematosus and has shown efficacy in Sjögren's syndrome in small studies [14,15]. This evidence concerns the gene TNFSF13B and Sjogren syndrome.